EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Biomarkers for the diagnosis and management of heart failure

Vincenzo Castiglione, Alberto Aimo iD, Giuseppe Vergaro, Luigi Saccaro, Claudio Passino, Michele Emdin

Heart Failure Reviews · 2022-03 · 27 (2) · 625-643

DOI: 10.1007/s10741-021-10105-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Heart Failure Reviews, online erschienen am 14.04.2021. Verfasst von Vincenzo Castiglione und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy. Hauptthemen laut MEDLINE: Heart Failure, Proteomics. Die Arbeit wurde bisher 486-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scuola Superiore Sant'Anna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure (HF) is a significant cause of morbidity and mortality worldwide. Circulating biomarkers reflecting pathophysiological pathways involved in HF development and progression may assist clinicians in early diagnosis and management of HF patients. Natriuretic peptides (NPs) are cardioprotective hormones released by cardiomyocytes in response to pressure or volume overload. The roles of B-type NP (BNP) and N-terminal pro-B-type NP (NT-proBNP) for diagnosis and risk stratification in HF have been extensively demonstrated, and these biomarkers are emerging tools for population screening and as guides to the start of treatment in subclinical HF. On the contrary, conflicting evidence exists on the role of NPs as a guide to HF therapy. Among the other biomarkers, high-sensitivity troponins and soluble suppression of tumorigenesis-2 are the most promising biomarkers for risk stratification, with independent value to NPs. Other biomarkers evaluated as predictors of adverse outcome are galectin-3, growth differentiation factor 15, mid-regional pro-adrenomedullin, and makers of renal dysfunction. Multi-marker scores and genomic, transcriptomic, proteomic, and metabolomic analyses could further refine HF management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureProteomicsBiomarkersHumansNatriuretic Peptide, BrainNatriuretic PeptidesPeptide FragmentsPrognosis

Stichwörter der Autor:innen

BiomarkersHeart failureInflammationNatriuretic peptidesSST2Troponin

Substanzen

BiomarkersNatriuretic PeptidesPeptide FragmentsNatriuretic Peptide, Brain

Autor:innen und Institutionen

  • Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
  • Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy. albertoaimo@libero.it.
  • Fondazione Toscana Gabriele Monasterio, Pisa, Italy. albertoaimo@libero.it.
  • Fondazione Toscana Gabriele Monasterio, Pisa, Italy.

ORCID-Profile: Alberto Aimo

Förderung

  • Scuola Superiore Sant'Anna

Zitieren

APA

Castiglione, V., Aimo, A., Vergaro, G., Saccaro, L., Passino, C., & Emdin, M. (2022). Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews, 27(2), 625-643. https://doi.org/10.1007/s10741-021-10105-w

Vancouver

Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews. 2022;27(2):625-643. doi:10.1007/s10741-021-10105-w

BibTeX
@article{Castiglione2022,
  author = {Castiglione, Vincenzo and Aimo, Alberto and Vergaro, Giuseppe and Saccaro, Luigi and Passino, Claudio and Emdin, Michele},
  title = {Biomarkers for the diagnosis and management of heart failure},
  journal = {Heart Failure Reviews},
  year = {2022},
  volume = {27},
  number = {2},
  pages = {625--643},
  doi = {10.1007/s10741-021-10105-w}
}
Kostenlos starten →